Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 11;16(1):63.
doi: 10.1186/s13098-024-01308-w.

Association between insulin resistance, metabolic syndrome and its components and lung cancer: a systematic review and meta-analysis

Jingxuan Liu #  1 , Rui Wang #  1 , Song Tan  2 , Xiaohu Zhao  1 , Aihua Hou  3
Affiliations
Review

Association between insulin resistance, metabolic syndrome and its components and lung cancer: a systematic review and meta-analysis

Jingxuan Liu et al. Diabetol Metab Syndr. .

Abstract

Background: A growing body of evidence points to the association between insulin resistance (IR), metabolic syndrome (MetS) and its components and lung cancer incidence, but remains controversial and unknown.

Methods: A systematic search was conducted through PubMed, Embase, Cochrane Library, the China National Knowledge Infrastructure (CNKI) and Wanfang databases for the corresponding studies. Each study reported the risk estimate and 95% confidence intervals (CI) for lung cancer, and a fixed effects model or random effects model was used for outcome.

Results: We included 31 publications involving 6,589,383 people with 62,246 cases of lung cancer. Diabetes mellitus (DM) (RR = 1.11, 95% CI 1.06-1.16, P = 0.000) and IR (RR = 2.35, 95% CI 1.55-3.58, P = 0.000) showed a positive association with lung cancer risk. BMI (RR = 0.66, 95% CI 0.54-0.81, P = 0.000) and HDL-C (RR = 0.88, 95% CI 0.79-0.97, P = 0.010) were negatively correlated with lung cancer. MetS(RR = 0.99, 95% CI 0.90-1.09, P = 0.801), TC (RR = 0.93, 95% CI 0.81-1.06, P = 0.274), TG (RR = 0.99, 95% CI 0.88-1.12,P = 0.884), LDL-C (RR = 1.01, 95% CI 0.87-1.16, P = 0.928), hypertension (RR = 1.01, 95% CI 0.88-1.15, P = 0.928), FBG (RR = 1.02, 95% CI 0.92-1.13, P = 0.677) and obesity (RR = 1.11, 95% CI 0.92-1.35, P = 0.280) were not associated with lung cancer.

Conclusion: Our study showed that the risk of lung cancer is correlated with DM, IR, BMI, and HDL-C. Timely control of these metabolic disorders may have a positive effect on preventing lung cancer. Trial registration Our study has been registered in the Prospective Register of Systematic Reviews (PROSPERO), ID: CRD42023390710.

Keywords: Diabetes; Insulin resistance; Lung cancer; Meta-analysis; Metabolic syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of literature screening
Fig. 2
Fig. 2
Relationship between metabolic factors and lung cancer. A MetS and lung cancer. B IR and lung cancer. C BMI and lung cancer. D HDL-C and lung cancer
Fig. 3
Fig. 3
Analysis of DM and TC. A Relationship between DM and lung cancer. B Relationship between TC and lung cancer (subgroup analysis). C Funnel plot of DM. D Funnel plot of TC
Fig. 4
Fig. 4
Summary data
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192644. - DOI - PubMed
    1. NCD Countdown 2030 collaborators NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392(10152):1072–1088. doi: 10.1016/S0140-6736(18)31992-5. - DOI - PubMed
    1. Freeman AM, Pennings N. Insulin resistance. In: Freeman AM, editor. StatPearls. Treasure Island: StatPearls Publishing; 2022.
    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Wood DE, Kazerooni EA, Aberle D, et al. NCCN guidelines insights: lung cancer screening, version 1.2022. J Natl Compr Canc Netw. 2022;20(7):754–764. doi: 10.6004/jnccn.2022.0036. - DOI - PubMed

LinkOut - more resources